EANS-News: Epigenomics Initiates Clinical Market Observation Study for Colorectal Cancer Blood Test

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

Berlin and Seattle, November 23, 2010 (euro adhoc) - Epigenomics AG,
the cancer diagnostics company, today announced that they have
initiated an observational clinical study for the Epi proColon test
to examine adoption patterns in the marketplace.

Epi proColon is the world's first CE-marked molecular diagnostic test
for the early detection of colorectal cancer in blood. This
diagnostic laboratory test was first launched in October 2009 in
Europe and is currently being marketed by Epigenomics to privately
insured individuals and self-payors in Germany, Austria and
Switzerland and through distributors in other markets.

With the clinical performance of the test's underlying biomarker,
Septin9, well established in numerous case control studies and a
large prospective screening study, the current study focuses on
behavioral and demographic aspects of current users of the test. The
observational study is expected to include approximately 300 primary
care physicians, enrolling up to 3,000 patients taking the Epi
proColon test in Germany and Switzerland. The study, which has
recently already been cleared by the Berlin Ethics Board, is expected
to be fully enrolled in 2011.

"While the preparedness to pay out of pocket among patients in Switzerland is
very high, Germans still tend to rely mostly on the public health care system",
explained Dr. Juergen Beck, Senior Vice President Medical Affairs at
Epigenomics. "The only non-invasive alternative to colonoscopy for colorectal
cancer screening that is currently reimbursed under the German public scheme is
a chemical stool test, which is outdated in performance and lacks convenience
and patient-friendliness. With this new study, we expect to learn more about
those individuals that opt to use our convenient blood test. We expect the
results of this study to help with both fine-tuning the positioning of the test
in the self-payor market segment and in seeking general reimbursement under the
public health care scheme."

-Ends-

Contact Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 0
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development for
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially
increasing the patient's chances of survival.

For development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc.
for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more
information, please visit Epigenomics' website at
www.epigenomics.com.

Notes for editors:

Epi proColon

Epi proColon, developed by Epigenomics, is a CE-marked test kit for
the detection of methylated DNA of the Septin9 gene in blood plasma.
This Septin9 biomarker has been shown in numerous clinical studies to
be closely associated with the presence of colorectal cancer and may
aid in the detection of this common cancer. Septin9 is one of the
best and most systematically validated biomarkers for the early
detection of colorectal cancer today. In particular, the recent
PRESEPT Study was a successful prospective evaluation of Epi proColon
detection of methylated Septin9 in a cohort of about 8,000
individuals representative of a typical screening population.

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the USA have not
been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade